Abstract |
The role of the renin-angiotensin-aldosterone system in the pathogenesis of hypertensive disease has long been recognized, and the interruption of this cascade with angiotensin-converting enzyme-I has been beneficial in the management of hypertension. Recently, a new class of drugs, the angiotensin receptor blockers, emerged, enlarging the antihypertensive armamentarium. Since elderly patients are more prone to adverse drug reactions, in this paper we review several trials, most of which were of short duration, on the efficacy and safety of angiotensin receptor blockers in the geriatric population with mild to moderate hypertension. These studies established that the drugs are well-tolerated, safe, and in most instances as efficacious as other classes of antihypertensive medications. Combination therapy with angiotensin receptor blockers and hydrochlorothiazide was additive, without any significant effect on the safety profile.
|
Authors | C E Okereke, F H Messerli |
Journal | The American journal of geriatric cardiology
(Am J Geriatr Cardiol)
2001 Jan-Feb
Vol. 10
Issue 1
Pg. 42-9
ISSN: 1076-7460 [Print] United States |
PMID | 11413935
(Publication Type: Journal Article, Review)
|
Chemical References |
- Angiotensin Receptor Antagonists
- Antihypertensive Agents
|
Topics |
- Aged
- Angiotensin Receptor Antagonists
- Antihypertensive Agents
(adverse effects, therapeutic use)
- Clinical Trials as Topic
- Humans
- Hypertension
(drug therapy)
- Treatment Outcome
|